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ABSTRACT
Objectives calprotectin (S100a8/a9) has been correlated 
with disease activity in rheumatoid arthritis (ra). the aim 
of this study was to investigate the predictive value of 
serum calprotectin for clinical response after starting and 
tapering anti-tumour necrosis factor treatment in ra.
Methods Serum samples and clinical outcomes were 
derived from two longitudinal ra studies. at baseline 
(starting or tapering of adalimumab or etanercept), 
calprotectin levels were determined by eliSa. in the 
Biologic individual Optimised treatment Outcome 
Prediction (BiO-tOP) study, treatment effect was assessed 
after 6 months using the european league against 
rheumatism (eUlar) response criteria. in the Dose 
reduction Strategies of Subcutaneous tnF inhibitors 
(DreSS) study, patients were classified at 18 months as 
being successfully dose reduced, discontinued or not able 
to reduce the dose. area under the receiver operating 
characteristic curves (aUc) were generated to evaluate 
the predictive value of calprotectin and logistic prediction 
models were created to assess its added value.
Results in the BiO-tOP study, calprotectin levels were 
higher in responders (n=50: 985 ng/ml (p25–p75: 
558–1417)) compared with non-responders (n=75: 645 
ng/ml (p25–p75: 415–973), p=0.04). aUc for predicting 
eUlar good response was 0.61 (95% ci 0.50 to 0.71). the 
prediction model with calprotectin (aUc 0.77, 95% ci 0.68 
to 0.85) performed similarly to the baseline model (aUc 
0.74, 95% ci 0.65 to 0.82, p=0.29). in the DreSS study, 
calprotectin levels were similar between the three groups 
(n=47; n=19; n=36) and calprotectin was not predictive 
for clinical response after tapering.
Conclusions Serum calprotectin has some predictive 
value for clinical response after starting anti-tnF 
treatment, although it has no added value to other clinical 
factors. in patients with low disease activity, serum 
calprotectin is not predictive for clinical response after 
tapering anti-tnF treatment.
Trial registration number ntr4647 (BiO-tOP study) and 
ntr3216 (DreSS study); Pre-results.
InTROduCTIOn
The introduction of biological disease-mod-
ifying antirheumatic drugs (bDMARD) has 
improved the treatment outcomes of rheu-
matoid arthritis (RA). However, approx-
imately 60% of patients with RA do not 
achieve good clinical response after 6 months 
of treatment with a bDMARD, including 
tumour necrosis factor inhibitors (TNFi).1 
Furthermore, tapering TNFi has been shown 
feasible in a large proportion of patients with 
RA with low disease activity but again, not in 
all patients.2 Non-responding after starting a 
TNFi or flaring after tapering of a TNFi are 
both undesirable, since a (short) period of 
high disease activity might cause worsening of 
physical functioning and radiographic joint 
progression.3 4 
The ability to accurately predict indi-
vidual response after starting or tapering of 
a TNFi might improve treatment outcomes 
compared with the current ‘trial-and-error’ 
Key messages
What is already known about this subject?
 ► Serum calprotectin (S100a8/a9) has been 
correlated with clinical and laboratory markers of 
disease activity in rheumatoid arthritis (ra).
What does this study add?
 ► We investigated the predictive value of serum 
calprotectin for clinical response after respectively 
starting and tapering anti-tumour necrosis factor 
(tnF) treatment in two longitudinal ra studies.
How might this impact on clinical practice?
 ► Serum calprotectin has no added predictive value 
to other clinical factors (such as 28-joint count 
Disease activity Score using c-reactive protein) for 
clinical response after starting anti-tnF treatment.
 ► in patients with low disease activity, serum 
calprotectin is not predictive for clinical response 
after tapering anti-tnF treatment.
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treatment. In patients who are unlikely to respond to (a 
certain) TNFi, starting another TNFi or bDMARD with 
another mode of action might potentially be more effec-
tive. In addition, when it can be predicted that tapering 
will be unsuccessful in a patient, tapering would not be 
attempted thereby preventing disease flares, minimising 
physician efforts and easing uncertainty in patients. 
Notably, in both scenarios, the gains would be better 
treatment outcomes, not lower direct costs per se.
Calprotectin (also known as S100A8/A9 and 
MRP8/14) might be a promising biomarker to predict 
clinical response to anti-TNF treatment. In contrast to 
acute phase proteins which are mainly of hepatic origin, 
calprotectin is released predominantly by granulocytes 
at sites of inflammation.5 It also diffuses easily from 
inflamed joints into the blood circulation because of its 
relatively low molecular weight.6
Previous studies have shown that serum calprotectin is 
cross-sectionally correlated with clinical and laboratory 
markers of disease activity in RA.7–11 Studies that have 
investigated the longitudinal predictive value of calpro-
tectin for clinical response to bDMARD treatment show 
however conflicting results. Choi et al demonstrated 
that serum calprotectin at baseline predicts response to 
treatment with respectively adalimumab (ADA), inflix-
imab and rituximab.12 However, in other studies baseline 
calprotectin could not predict responsiveness to treat-
ment with a bDMARD.8 13–15 On the other hand, decreased 
calprotectin levels after 4 weeks of bDMARD treatment 
were consistently predictive of clinical response.12 13 And 
in patients with juvenile idiopathic arthritis (JIA) in clin-
ical remission, high calprotectin levels at the moment 
of discontinuation of etanercept (ETN) were associated 
with subsequent flare.16 This association has not yet been 
investigated in RA.
Before serum calprotectin can be used to guide clinical 
decision-making in daily practice, it must meet minimal 
validation criteria, as proposed by the OMERACT Soluble 
Biomarker Group.17 Furthermore, the prediction of the 
clinical outcome should have therapeutic consequences. 
Achieving good response after starting treatment and 
maintaining response after tapering treatment are both 
clinical important scenarios with uncertainty on clinical 
outcome. Therefore, the aim of this study was to investi-
gate the predictive value of serum calprotectin for clinical 
response after starting and tapering anti-TNF treatment 
in patients with RA.
MeTHOds
study population
Baseline serum samples and clinical outcomes of patients 
with RA starting ADA or ETN were derived from the 
Biologic Individual Optimised Treatment Outcome 
Prediction (BIO-TOP) study (Dutch trial register, 
NTR4647).18 In this prospective longitudinal prediction 
study, patients with RA >18 years starting with or switching 
to a bDMARD were enrolled between 2014 and 2016. The 
same data were collected of patients with RA included 
in the dose tapering arm of the Dose Reduction Strat-
egies of Subcutaneous TNF Inhibitors (DRESS) study 
(Dutch trial register, NTR3216)19: an 18-month open 
randomised clinical trial investigating non-inferiority of 
a dose reduction strategy of ADA or ETN compared with 
usual care. In the DRESS study, patients with RA using 
ADA or ETN at any stable dose and interval for at least 
6 months with stable low disease activity at two subse-
quent visits were enrolled in 2011 and 2012. Full details 
of this study have been reported previously.20 These two 
studies were performed in two hospitals in the Nether-
lands (Sint Maartenskliniek Nijmegen and Maartensk-
liniek Woerden) and were both approved by the local 
ethics committee (CMO region Arnhem-Nijmegen, 
NL47946.091.14 and NL37704.091.11). Procedures 
followed were in accordance with the Declaration of 
Helsinki and all patients gave written informed consent.
Clinical assessments
In the BIO-TOP study, treatment effect was assessed at 
month 6 with the commonly used European League 
Against Rheumatism (EULAR) response criteria (good 
vs moderate/no response).21 In the DRESS study, three 
clinical outcomes were defined at month 18: successful 
dose reduction, successful discontinuation and not able 
to reduce dose. Successful dose reduction was defined as 
using the TNFi at a longer interval or lower dose than 
at enrolment with concurrent low disease activity. In 
both studies, calprotectin levels were not available when 
disease activity was assessed, preventing expectation bias.
serum calprotectin measurement
At baseline (starting or tapering of ADA or ETN) serum 
samples were collected and centrifuged within 1 hour. 
Subsequently the samples were stored at −80°C until anal-
ysis took place (October 2016). Calprotectin levels were 
measured in the laboratory of the University of Münster 
using an ELISA, as described previously.22 The readers of 
the assay were blinded for the disease activity and medi-
cation use of patients.
statistical analysis
Descriptive statistics are reported as either mean (±SD), 
median (IQR (p25–p75)) or frequency depending on 
data distribution. Baseline characteristics were compared 
using Student’s t-test (or, if not normally distributed, 
Wilcoxon rank-sum test) and χ2 test for continuous 
and categorical data, respectively. Correlations between 
calprotectin and clinical variables (ie, age, gender, 
disease duration, rheumatoid factor (RF), anti-citrulli-
nated protein antibodies, 28-joint count Disease Activity 
Score using C-reactive protein (DAS28-CRP) and its 
components, CRP and erythrocyte sedimentation rate 
(ESR)) were cross-sectionally explored by Spearman 
correlation analysis. In the BIO-TOP study, discontinu-
ation of the TNFi before 6 months due to lack of effect 
was regarded as non-response and for discontinuation 
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due to other reasons the clinical response at month 3 was 
carried forward.
Area under the receiver operating characteristic curves 
(AUC) were generated to evaluate the predictive value 
of baseline serum calprotectin levels for respectively 
EULAR good response (yes vs no), successful dose reduc-
tion (yes vs no), successful discontinuation (yes vs no) 
and not able to reduce dose (yes vs no). For AUCs with 
a 95% CI lower bound ≥0.5, we additionally performed 
logistic prediction modelling. First, univariate logistic 
regression analyses were performed to assess which demo-
graphic, disease-specific and treatment-specific variables 
at baseline were associated with the treatment outcome. 
Variables that showed an association in the univariate 
analyses were entered in a multivariate logistic regression 
analysis using stepwise backwards selection to construct 
a baseline prediction model taking into account the rule 
of thumb of 1 predictor per 10 patients. Subsequently, 
we added calprotectin to the baseline model and tested 
the equality of the two AUCs by using the algorithm 
suggested by DeLong et al.23 Missing data in this analysis 
were addressed using multiple imputation. A p value 
<0.05 was considered statistically significant. All analyses 
were performed using STATA V.13.1.
ResulTs
Patient characteristics
Baseline serum samples and 6-month clinical outcome 
data were available of 50 patients starting ADA and 75 
patients starting ETN in the BIO-TOP study. Additionally, 
102 of 121 (84%) patients randomised to the tapering 
arm of the DRESS study had available baseline serum 
samples of whom 38 patients were treated with ADA 
and 64 patients with ETN. Baseline characteristics of 
the included patients in both cohorts are summarised in 
table 1.
Serum calprotectin at baseline was similar between 
patients who started TNFi and patients who tapered 
TNFi: 680 ng/mL (p25–p75: 433–1252) vs 612 ng/mL 
(p25–p75: 475–927) (p=0.15). In the BIO-TOP study, 
calprotectin levels were weakly to moderately signifi-
cantly correlated with DAS28-CRP (r=0.32, p<0.001), ESR 
(r=0.41, p<0.001) and CRP (r=0.57, p<0.001) at baseline. 
Also, calprotectin was significantly higher in RF-positive 
patients (r=0.19, p=0.03). In the DRESS study, calpro-
tectin levels were only significantly correlated with CRP 
(r=0.21, p=0.03).
Baseline calprotectin levels and correlation with response to 
treatment
Fifty of 125 (40%) patients starting a TNFi achieved 
EULAR good response at month 6. Baseline calprotectin 
levels were higher in responders (985 ng/mL (p25–p75: 
558–1417)) compared with non-responders (645 ng/
mL (p25–p75: 415–973), p=0.04) (figure 1, left panel). 
Responders also had a higher DAS28-CRP (4.4 (SD 0.8) 
vs 3.8 (SD 1.2), p=0.003) and a higher CRP (8 mg/L 
(p25–p75: 2–25) vs 3 mg/L (p25–p75: 0–14), p=0.008) 
at baseline. More patients achieved good response after 
ETN treatment (38 of 75 (51%) patients) compared with 
ADA treatment (12 of 50 (24%) patients) (p=0.003). This 
Table 1 Baseline characteristics
BIO-TOP 
study n=125
DRESS 
study n=102
Demographics
  Age (years)* 57 (12) 59 (10)
  Female gender 81 (65) 62 (61)
  Disease duration (years)† 4 (1–10) 11 (6–17)
  RF positive 74/123 (60) 80 (78)
  ACPA positive 65/116 (56) 73 (72)
Disease characteristics
  DAS28-CRP* 4.0 (1.1) 2.2 (0.6)
  TJC† 4 (2–9) 0 (0–1)
  SJC† 4 (1–7) 0 (0–0)
  PGA, VAS 0–100 mm*‡ 62 (20) 23 (17)
  CRP (mg/L)† 5 (1–19) 3 (3)
  ESR (mm/hour)†‡ 17 (7-31) 12 (7–20)
  Calprotectin (ng/mL)† 680 (433–
1252)
612 (475-
927)
Treatment characteristics
  Number of previous 
bDMARDs†
0 (0–1) 0 (0–1)
  Current TNFi
   ADA 50 (40) 38 (37) 
   ETN 75 (60) 64 (63) 
  Duration current 
TNFi (years)†
NA 3 (2–6)
  Concomitant treatment 
   csDMARDs 97 (78) 59 (58) 
   MTX 66 (53) 46 (45) 
   NSAIDs 80 (64) 57 (56) 
   Oral glucocorticoids 22 (18) 5 (5) 
Data presented as number (%) unless otherwise noted.
*Mean (SD).
†Median (p25–p75).
‡Missing data BIO-TOP study; in eight patients (6%) PGA is 
missing and in nine patients (7%) ESR is missing. If PGA was 
missing, DAS28-CRP was calculated with three variables: TJC, 
SJC and CRP.
ACPA, anti-citrullinated protein antibodies; ADA, adalimumab; 
bDMARD, biological disease-modifying antirheumatic 
drug; BIO-TOP, Biologic Individual Optimised Treatment 
Outcome Prediction; CRP, C-reactive protein; csDMARD, 
conventional synthetic DMARD; DAS28-CRP, 28-joint count 
Disease Activity Score using CRP; DRESS, Dose Reduction 
Strategies of Subcutaneous TNF Inhibitors; ESR, erythrocyte 
sedimentation rate; ETN, etanercept; MTX, methotrexate; NA, not 
applicable; NSAID, non-steroidal anti-inflammatory drug; PGA, 
patient global assessment of disease activity; RF, rheumatoid 
factor; SJC, swollen joint count; TJC, tender joint count; TNFi, 
tumour necrosis factor inhibitor; VAS, visual analogue scale.
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can be explained by the fact that in our hospital ADA 
was reserved for patients who had failed on ETN treat-
ment. As a consequence, patients treated with ADA were 
presumably more refractory to treatment with a TNFi.
Of the patients who tapered ADA or ETN, 47 (46%) 
successfully reduced the TNFi dose, 19 (19%) success-
fully discontinued the TNFi and 36 (35%) could not 
reduce the TNFi dose. Calprotectin levels at baseline 
were similar between these groups: 599 ng/mL (p25–p75: 
473–965), 629 ng/mL (p25–p75: 454–896) and 624 ng/
mL (p25–p75: 514–931) (p=0.80) (figure 1, right panel). 
The patient group that could not reduce the dose had a 
lower percentage of RF-positive patients (24 of 36 (67%) 
vs 56 of 66 (85%), p=0.03) and had a near significantly 
higher DAS28-CRP at baseline (2.4 (SD 0.7) vs 2.1 (SD 
0.6), difference +0.3 (95% CI −0.001 to 0.51)).
Predictive value of calprotectin for clinical response after 
starting a TnFi
The AUC for predicting EULAR good response versus 
EULAR moderate/no response using baseline serum 
calprotectin was 0.61 (95% CI 0.50 to 0.71), while for 
respectively baseline DAS28-CRP and CRP AUCs were: 
0.68 (95% CI 0.58 to 0.77) and 0.64 (95% CI 0.54 to 0.74).
Subgroup analyses were performed for serum calpro-
tectin, in which the AUC tended to be greater in patients 
who started treatment with ADA (0.68, 95% CI 0.49 to 
0.88) compared with patients who started ETN (0.49, 
95% CI 0.36 to 0.63) (p=0.11). There were no statistically 
significant differences in AUCs for concomitant conven-
tional synthetic DMARD (csDMARD) use (yes vs no) or 
oral glucocorticoid use (yes vs no).
The prediction model with calprotectin (AUC 0.77, 
95% CI 0.68 to 0.85) performed similarly to the base-
line model (backward selected variables: patient global 
assessment of disease activity, DAS28-CRP, used TNFi 
(ADA vs ETN) and the interaction between calprotectin 
and used TNFi) (AUC 0.74, 95% CI 0.65 to 0.82, p=0.29) 
(Figure 2).
Predictive value of calprotectin for clinical response after 
tapering a TnFi
Serum calprotectin was not predictive for clinical 
response after tapering anti-TNF treatment.
AUCs were 0.52 (95% CI 0.40 to 0.63) for predicting 
successful dose reduction, 0.53 (95% CI 0.39 to 0.67) for 
successful discontinuation and 0.54 (95% CI 0.42 to 0.66) 
for not able to reduce dose. Also, DAS28-CRP and CRP 
were not predictive for the three treatment outcomes 
with corresponding AUCs varying from 0.54 to 0.61 for 
DAS28-CRP and from 0.46 to 0.56 for CRP. Subgroup 
analyses showed no statistically significant differences 
in AUCs for used TNFi (ADA vs ETN), concomitant 
csDMARD use (yes vs no) or oral glucocorticoid use (yes 
vs no). Logistic prediction modelling was deemed unnec-
essary, since the univariate AUCs already demonstrated 
no predictive value.
dIsCussIOn
In this study, we have investigated the predictive value 
of baseline serum calprotectin for clinical response after 
both starting and tapering of anti-TNF treatment in 
patients with RA in daily practice. We have shown that 
serum calprotectin has some predictive value for clinical 
response after starting anti-TNF treatment, although 
it has no added value to other clinical factors, such as 
DAS28-CRP. Moreover, serum calprotectin was not 
predictive for clinical response after tapering anti-TNF 
Figure 1 Distribution of baseline serum calprotectin levels by outcome. Left panel. BIO-TOP study: 125 patients with 
rheumatoid arthritis (RA) who started a TNFi. Right panel. DRESS study: 102 patients with RA who tapered a tumour necrosis 
factor inhibitor (TNFi). BIO-TOP, Biologic Individual Optimised Treatment Outcome Prediction; DRESS, Dose Reduction 
Strategies of Subcutaneous TNF Inhibitors; EULAR, European League Against Rheumatism. 
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treatment in patients with low disease activity. We would 
like to discuss our findings in more detail below.
Our study supports the previous findings of a meta-anal-
ysis which showed that serum calprotectin levels were 
positively correlated to clinical disease activity measures 
including DAS28-CRP and CRP.24 However, in our study 
calprotectin levels at baseline were not significantly 
higher in the patient group with high disease activity that 
started a TNFi compared with the patient group with low 
disease activity that tapered a TNFi. Second, we could 
confirm in accordance with a previous study that baseline 
serum calprotectin levels were higher in responders after 
starting a TNFi compared with non-responders.12 Next, 
we demonstrated that calprotectin has some predictive 
value for clinical response after starting a TNFi, but has no 
added value to clinical factors routinely measured in RA 
in daily practice, such as DAS28-CRP. This lack of added 
value of calprotectin was observed before in prediction of 
response after starting a TNFi in JIA.16 Thus, measuring 
baseline serum calprotectin levels seems unable to help 
optimising therapeutic decision-making in daily practice 
due to its substantial overlap with already used disease 
activity measures (DAS28-CRP and CRP).
Calprotectin tended to be a better predictor for 
response to ADA treatment than ETN treatment, but this 
was not significant due to the lower group sizes. Since 
ETN was the first-choice bDMARD at our hospital, this 
finding might indicate that a serum calprotectin level 
without previous treatment with a TNFi has less predic-
tive value than a serum calprotectin level after previous 
treatment with a TNFi for clinical response to the next 
TNFi. This seems to match with previous findings in 
other studies showing that decreased calprotectin levels 
after 4 weeks of bDMARD treatment were consistently 
predictive of clinical response to the same bDMARD.12 13
In patients who tapered treatment with a TNFi, we found 
no differences in baseline calprotectin levels between 
the three treatment outcome groups. Also, calprotectin 
had similar AUC characteristics as DAS28-CRP and CRP. 
We assume that calprotectin behaves like an acute phase 
protein. Since tapering was only performed in patients 
with a low disease activity, there was correspondingly a low 
intervariability in CRP and calprotectin levels at baseline. 
As a result, measuring serum calprotectin levels seems 
unable to distinguish patients who are doing well while 
using a TNFi from those who are doing well because of 
a TNFi.
A strength of our study is that we investigated the predic-
tive value of serum calprotectin for clinical response after 
both starting and tapering of ADA and ETN in a large 
number of patients with RA treated in the same hospital. 
We specifically focused on the added value of calpro-
tectin for starting a TNFi and to the best of our knowl-
edge were the first to investigate serum calprotectin for 
clinical response after tapering a TNFi in RA.
A limitation of our study might be that we have not 
longitudinally measured calprotectin levels after starting 
or tapering TNFi. Although other studies have shown that 
decreased calprotectin levels after 4 weeks of bDMARD 
treatment were predictive of clinical response,12 13 we 
believe that a biomarker measured after initiating starting 
or tapering of a bDMARD is less relevant, because the 
treatment decision is then already made and future 
treatment decisions can be based on actual clinical 
response rather than changes in biomarkers. Preferably, 
a biomarker would be identified that can prevent starting 
Figure 2 Added predictive value of calprotectin for clinical response after starting a tumour necrosis factor inhibitor 
(TNFi). AUC, area under the receiver operating characteristic curve. 
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or tapering of a bDMARD in patients who are likely to 
fail on it.
Another limitation might be the considerable coeffi-
cient of variation (CV) for calprotectin due to its limited 
linearity range.7 We tried to minimalise it by measuring 
each sample in three different dilutions and accepting 
results as reliable if all values coincided after recalcu-
lation. There is conflicting evidence whether serum or 
plasma is preferable for the measurement of calpro-
tectin. A systematic review has demonstrated that the 
CV for calprotectin is lowest in studies using serum,7 but 
Nordal et al found similar variability in calprotectin levels 
when measured in plasma and serum.25
Also, calprotectin levels are not a specific marker for 
RA activity. Calprotectin levels might be affected by the 
presence of cardiovascular disease and obesity compli-
cating prediction of clinical response to treatment of 
RA.26 27
Furthermore, we included only patients with estab-
lished RA and therefore our results might not be valid for 
patients with early RA, especially since it has been shown 
that calprotectin is a better predictor of response to 
methotrexate therapy in patients with early RA (<1 year) 
as compared with later onset of disease (>1 year) (10). 
This difference might be explained by the fact that 
neutrophil granulocytes are more prevalent in early 
RA.28 However, the heterogeneity in treatment duration 
in our study population allows translation of the results 
in daily practice.
So far, studies have failed to consistently identify a single 
biomarker that can predict individual treatment response 
after starting or tapering TNFi with sufficient predictive 
value to be used in the individual patient with RA.29 30 
We presume that prediction of clinical response to treat-
ment is difficult due to the complex pathobiology of RA 
and the potential unknown effects of TNFi’s. As a conse-
quence, measuring random laboratory markers is associ-
ated with a low a priori chance of finding a biomarker. 
Furthermore, clinical response (based on changes in the 
DAS28 compared with baseline) is not solely the result of 
inflammatory RA activity but can be confounded by many 
other factors (eg, psychosocial) troubling prediction by a 
biomarker.
In conclusion, serum calprotectin has some predictive 
value for clinical response after starting anti-TNF treat-
ment in RA, but it has no added value to other clinical 
factors such as DAS28-CRP. In patients with low disease 
activity, serum calprotectin was not predictive for clinical 
response after tapering anti-TNF treatment.
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